Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma

Abstract Introduction Avelumab and pembrolizumab are approved immune checkpoint inhibitors (ICIs) for advanced urothelial carcinoma (UC) that are used as maintenance and salvage therapies, respectively. The aim of this study was to highlight patterns of extreme response and support the development o...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Martina Catalano, Irene de Gennaro Aquino, Ismaela Anna Vascotto, Adriana Guarino, Silvia Mancini, Laura Doni, Alexandra Paulet, Virginia Rossi, Roberta Giorgione, Gabriella Nesi, Lorenzo Antonuzzo, Giandomenico Roviello
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2025-10-01
Colecção:	Oncology and Therapy
Assuntos:	Avelumab Pembrolizumab Immunotherapy Biomarkers
Acesso em linha:	https://doi.org/10.1007/s40487-025-00387-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!